FGF21 and obesity due to melanocortin 4 receptor deficiency: As a novel endocrine hormone, FGF21 has profound effects on the regulation of metabolic parameters such as glucose and lipid homeostasis, and represents a promising potential therapeutic target in type 2 diabetes (T2D) and obesity [3].